道彤投资

道彤投资

@daltonventure

以生命科学为根，向硬科技生长

111 articles

Articles

Dalton Venture and Portfolio Company Gestalt Technology Win Jazzyear and TMTpost Honors Including Annual Healthcare Best Investment Firm TOP30 and 2026H1 Biopharma Pioneer TOP20

Dalton Venture and Portfolio Company Gestalt Technology Win Jazzyear and TMTpost Honors Including Annual Healthcare Best Investment Firm TOP30 and 2026H1 Biopharma Pioneer TOP20

Recently, Jazzyear unveiled its "2025-2026 China Tech Industry Investment Ranking" and TMTpost's "2026 H1 Pioneers List" was announced. **Dalton Venture** took home three awards across both rankings: "**2025-2026 Top 30 Best Healthcare Investment Firms**," "**2026 H1 Top 20 Pioneers in Biopharma**," and "**2026 H1 Top 10 Early-Stage Fundraising Pioneers**."

道彤投资·
What Happens After AI Starts Doing Science? | Dalton Venture AI4S Event Registration Now Open

What Happens After AI Starts Doing Science? | Dalton Venture AI4S Event Registration Now Open

More than 2,000 years ago, humanity gazed up at the stars, probing the laws of the cosmos. Three centuries ago, scientists built the modern scientific framework through experimentation and mathematics. Every leap in scientific development has been accompanied by new tools, new methods — and shifts in how humans explore the unknown.

道彤投资·
From Early Innovation to Industry Recognition: A Map of Dalton Venture's Specialized and Innovative Portfolio Companies

From Early Innovation to Industry Recognition: A Map of Dalton Venture's Specialized and Innovative Portfolio Companies

"Specialized, refined, distinctive, and innovative" enterprises are increasingly becoming a key benchmark for assessing the growth quality of China's technology and innovation companies. It represents not only a company's technical strength, innovation capability, and growth potential in niche sectors, but also serves as external validation from the industrial system of the value of outstanding SMEs. Recently, **Xuanyu Medical**, a **Dalton Venture family company**, was once again named to **Shanghai's second batch of 2026 specialized, refined, distinctive, and innovative SMEs. This marks Xuanyu Medical's continued recognition following its 2023 selection.

道彤投资·
Dalton Venture Honored on Diyixinsheng's Q2 2026 China Most Active Investors Rankings, Winning "Top 30 Most Active Early-Stage Investment Institutions" and "Top 10 Most Active Healthcare Investment Institutions" | Dalton Honor

Dalton Venture Honored on Diyixinsheng's Q2 2026 China Most Active Investors Rankings, Winning "Top 30 Most Active Early-Stage Investment Institutions" and "Top 10 Most Active Healthcare Investment Institutions" | Dalton Honor

Recently, Diyixinsheng released its Q2 2026 China Most Active Investment Firms rankings. The list evaluated firms across multiple dimensions including investment activity, fundraising, exits, IPOs, service transactions, post-investment tech support, and market influence. **Dalton Venture was honored with two awards: "Top 30 Most Active Early-Stage Investment Firms" and "Top 10 Most Active Investment Firms in Healthcare."**

道彤投资·
NewPro Closes Tens of Millions of RMB in Pre-A Funding Led by Dalton Venture and SSCI Leading Fund, Achieves FDA Self-GRAS Certification for Self-Developed Lactoferrin | Dalton Venture News

NewPro Closes Tens of Millions of RMB in Pre-A Funding Led by Dalton Venture and SSCI Leading Fund, Achieves FDA Self-GRAS Certification for Self-Developed Lactoferrin | Dalton Venture News

Recently, **NewPro Bioworks (Shanghai Xinyicui Biotechnology Co., Ltd.) announced the completion of a Pre-A funding round worth tens of millions of RMB**. This round was jointly led by **SSCI Leading Fund and Aochuang Pioneer Fund — the latter established by Dalton Venture in partnership with listed industry player OPM Biosciences, making it the first bio-manufacturing industry CVC fund in the Yangtze River Delta region**. Meanwhile, the company's self-developed precision-fermented lactoferrin product

道彤投资·
Dalton Venture Backs Invasive BCI, Active Technologies' 330 Million Yuan Angel Round Sets New Domestic Record for Brain-Computer Interface Funding | Dalton News

Dalton Venture Backs Invasive BCI, Active Technologies' 330 Million Yuan Angel Round Sets New Domestic Record for Brain-Computer Interface Funding | Dalton News

On August 3, **Shanghai Initiative Technology Co., Ltd. (hereinafter referred to as "Initiative Technology") announced the completion of a 330 million RMB angel funding round, setting a new record for angel-round financing in China's brain-computer interface sector. This round was led by CASSTAR, with co-investment from Dalton Venture, Legend Star, Unity Ventures, Inno Angel Fund, BGI Songhe Bio Fund, LYFE Capital, and Jiadao Capital**. The proceeds will be mainly used for facility expansion, equipment upgrades, and clinical trial advancement.

道彤投资·
Rongzi China Releases 2025-2026 Annual Industrial Investment Rankings, Dalton Venture Named "Best Investment Firm in China's Healthcare Sector" | Dalton Honor

Rongzi China Releases 2025-2026 Annual Industrial Investment Rankings, Dalton Venture Named "Best Investment Firm in China's Healthcare Sector" | Dalton Honor

On July 30, Rongzi China unveiled its 2025-2026 China Industrial Investment Rankings. Dalton Venture was named **2025-2026 Best Investment Institution in China's Healthcare Sector**, recognized for its professional capabilities across the full investment lifecycle and outstanding performance.

道彤投资·
Cost Cut by 50%, World's First 1,000-Ton-Scale Enzymatic Recycling Continuous Production Line Nears Launch as Source Tian Biotechnology Closes 100 Million Yuan Series A | Dalton Venture Family

Cost Cut by 50%, World's First 1,000-Ton-Scale Enzymatic Recycling Continuous Production Line Nears Launch as Source Tian Biotechnology Closes 100 Million Yuan Series A | Dalton Venture Family

Recently, **Dalton Venture portfolio company Yuantian Biotechnology (Tianjin) Co., Ltd.** (hereinafter referred to as "Yuantian Biotech") announced the completion of a 100-million-yuan Series A funding round. This round was led by Guotai Haitong and Jinqiao Fund, with follow-on investments from existing shareholders including Beiyang Haitang Fund. **The proceeds will be primarily used for technology iteration of its 100,000-ton production line, early-stage construction, and market promotion.**

道彤投资·
Dalton Venture Appoints New Member to Deepen Hong Kong Strategic Layout | Advancing to a New Stage of International Investment

Dalton Venture Appoints New Member to Deepen Hong Kong Strategic Layout | Advancing to a New Stage of International Investment

As its Hong Kong strategic layout continues to deepen, Dalton Venture is further refining its international investment system. **In July 2026, Mr. Chen Yaochao officially joined Dalton Venture as Managing Director and Head of the Hong Kong Fund. Going forward, he will take full responsibility for the operation, management, and strategic expansion of Dalton Venture's Hong Kong fund**, driving the firm's connectivity to resources in Hong Kong and international capital markets, and further strengthening Dalton Venture's cross-border investment capabilities in life sciences, health, and technology.

道彤投资·
How to Invest in Brain-Computer Interfaces? Dalton Venture's Lin Zhengcheng Breaks Down the Underlying Investment Logic at WAIC

How to Invest in Brain-Computer Interfaces? Dalton Venture's Lin Zhengcheng Breaks Down the Underlying Investment Logic at WAIC

**During the 2026 World Artificial Intelligence Conference (WAIC), Lin Zhengcheng, Partner at Dalton Venture, was invited to join Observer Network's *Zhi Guan WAIC 2026* livestream for nearly an hour of in-depth discussion on frontier technologies including brain-computer interfaces and AI for Science.** Rather than chasing industry buzzwords, Dalton Venture hoped to use this opportunity to present a long-developed research framework: as artificial intelligence continues to push toward the frontiers of science, the life sciences

道彤投资·